Does the development of new medicinal products in the European Union address global and regional health concerns?

Population Health Metrics

Volumn 8, Issue , 2010, Pages

  Catalá López, Ferrán ^a,b   García Altés, Anna ^a,c   Álvarez Martín, Elena ^d   Gènova Maleras, Ricard ^e   Morant Ginestar, Consuelo ^e  

^a Fundacion Instituto de Investigacion en Servicios de Salud   (Spain)

^b Ministry of Health and Social Policy   (Spain)

^c Catalan Agency for Health Information   (Spain)

^d UNIVERSIDAD REY JUAN CARLOS   (Spain)

^e Regional Health Council   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; HERBACEOUS AGENT; ORPHAN DRUG;

DATA SET; DISABILITY; DISEASE INCIDENCE; DRUG DEVELOPMENT; EUROPEAN COMMISSION; EUROPEAN UNION; GLOBAL PERSPECTIVE; MEDICINE; MORBIDITY; MORTALITY; PHARMACEUTICAL INDUSTRY; POLICY MAKING; PUBLIC HEALTH;

ANUS DISEASE; ARTICLE; ATTRIBUTABLE RISK; BIOGEOGRAPHIC REGION; BLOOD DISEASE; CARDIOVASCULAR DISEASE; CORRELATION ANALYSIS; DIABETES MELLITUS; DISABILITY; DISABILITY ADJUSTED LEFT YEAR; DRUG INDICATION; DRUG INFORMATION; DRUG MARKETING; DRUG MECHANISM; ENDOCRINE DISEASE; EUROPEAN UNION; GASTROINTESTINAL DISEASE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH HAZARD; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MORBIDITY; MORTALITY; MUSCULOSKELETAL DISEASE; NEUROPSYCHIATRY; PARASITOSIS; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; SENSE ORGAN; SENSORY DYSFUNCTION; UROGENITAL TRACT DISEASE;

EUROPE;

EID: 78650297080     PISSN: None     EISSN: 14787954     Source Type: Journal    
DOI: 10.1186/1478-7954-8-34     Document Type: Article

References (31)

1. de Abajo FJ. Medications as a solution and a problem for public health. Brief overview of the pharmacoepidemiologic objectives. Rev Esp Salud Publica 2001, 75(4):281-3.
2. Commission European Volume 9A of the Rules Governing Medicinal Products in the European Union - Pharmacovigilance for Medicinal Products for Human Use 2008, Brussels: European Commission, (accessed January 14, 2010), Commission European., http://ec.europa.eu/enterprise/sectors/pharmaceuticals/files/eudralex/vol-9/pdf/vol9a_09-2008_en.pdf
3. European Medicines Agency Central authorisation of medicines. (accessed December 13, 2010), European Medicines Agency., http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000109.jspandmurl=menus/about_us/about_us.jspandmid=WC0b01ac0580028a47
4. Murray CJL, Lopez AD. The Global Burden of Disease. A comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2010. The Harvard School of Public Health on behalf of the World Health Organization and the World Bank 1996, Boston: Harvard University Press.
5. Mathers CD, Vos ET, Stevenson CE, Begg SJ. The burden of disease and injury in Australia. 2001, 79:1076-1084. Bull World Health Organ.
6. World Bank World Development Report 1993, Investing in Health 1993, Washington D.C.: World Bank, World Bank.
7. World Health Organization Ad Hoc Committee on Health Research relating to future intervention options: investing in health research and development 1996, Geneva: World Health Organization, World Health Organization.
8. European Commission, Directorate General for Enterprise and Industry The Register of medicinal products for human use authorised by the Community under the centralised procedure. Published in accordance with Article 12 of Regulation (EEC) No 2309/93 2009, Brussels: European Commission, (accessed February 2, 2010), European Commission, Directorate General for Enterprise and Industry., http://ec.europa.eu/enterprise/sectors/pharmaceuticals/documents/community-register/html/index_en.htm
9. European Medicines Agency The European Public Assessment Report (EPAR) for authorised medicinal products for human use 2010, London: European Medicines Agency, (accessed February 2, 2010), European Medicines Agency., http://www.ema.europa.eu/htms/human/epar/a.htm
10. World Health Organization The Global Burden of Disease: 2004 update 2008, Geneva: World Health Organization, (accessed January 25, 2010), World Health Organization., http://www.who.int/evidence/bod
11. World Health Organization Disease country estimates. Death and DALY estimates for 2004 by cause for WHO Member States 2009, Geneva: World Health Organization, (accessed January 25, 2010), World Health Organization., http://www.who.int/healthinfo/global_burden_disease/gbddeathdalycountryestimates2004.xls
12. Barbui C, Garattini S. Regulatory policies on medicines for psychiatric disorders: is Europe on target?. Br J Psychiatry 2007, 190:91-3. 10.1192/bjp.bp.106.024794, 17267922.
13. Apolone G, Joppi R, Bertele' V, Garattini S. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. Br J Cancer 2005, 93(5):504-9. 10.1038/sj.bjc.6602750, 2361592, 16136026.
14. Garattini S, Bertele' V. Efficacy, safety, and cost of new anticancer drugs. BMJ 2002, 325(7358):269-71. 10.1136/bmj.325.7358.269, 1123779, 12153927.
15. Garattini S, Bertele' V. Efficacy, safety and cost of new cardiovascular drugs: a survey. Eur J Clin Pharmacol 2003, 59(8-9):701-6. 10.1007/s00228-003-0634-y, 12961050.
16. Bertele' V, Assisi A, Di Muzio V, Renzo D, Garattini S. New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval. Eur J Clin Pharmacol 2007, 63(9):879-89.
17. Garattini S, Bertele' V. Efficacy, safety and cost of new drugs acting on the central nervous system. Eur J Clin Pharmacol 2003, 59(1):79-84.
18. Garattini S, Bertele' V. How can we regulate medicines better?. BMJ 2007, 335(7624):803-5. 10.1136/bmj.39281.615706.94, 2034743, 17947785.
19. Bassi L, Bertele' V, Garattini S. European regulatory policies on medicines and public health needs. Eur J Public Health 2003, 13(3):246-51. 10.1093/eurpub/13.3.246, 14533728.
20. Garattini S, Bertele' V. Adjusting Europe's drug regulation to public health needs. Lancet 2001, 358:64-7. 10.1016/S0140-6736(00)05258-2, 11454401.
21. European Commission, Pharmaforum From assessing innovative value of pharmaceuticals to pricing and reimbursement decisions 2008, Brussels: European Commission, (accessed February 25, 2010), European Commission, Pharmaforum., http://ec.europa.eu/pharmaforum/docs/pricing_assessing_en.pdf
22. European Commission, Pharmaforum Characterisation of the Value of Innovative Medicines 2008, Brussels: European Commission, (accessed February 25, 2010), European Commission, Pharmaforum., http://ec.europa.eu/pharmaforum/docs/pricing_innovative_en.pdf
23. Dorsey ER, de Roulet J, Thompson JP, Reminick JI, Thai A, White-Stellato Z, Beck CA, George BP, Moses H. Funding of US biomedical research, 2003-2008. JAMA 2010, 303(2):137-43. 3, 10.1001/jama.2009.1987, 20068207.
24. Gross CP, Anderson GF, Powe NR. The relation between funding by the National Institutes of Health and the burden of disease. N Engl J Med 1999, 340(24):1881-7. 10.1056/NEJM199906173402406, 10369852.
25. Curry CW, De AK, Ikeda RM, Thacker SB. Health burden and funding at the Centers for Disease Control and Prevention. Am J Prev Med 2006, 30(3):269-76. 10.1016/j.amepre.2005.10.028, 16476645.
26. Catalá López F, Álvarez Martin E, Gènova Maleras R, Morant Ginestar C. Relationship between research funding in the Spanish National Health System and the burden of disease. Rev Esp Salud Publica 2009, 83(1):137-51.
27. Global Forum for Health Research The 10/90 Report on Health Research 2000 2000, Geneva: Global Forum for Health Research, (accessed April 13, 2010), Global Forum for Health Research., http://www.globalforumhealth.org/layout/set/print/Media-Publications/Publications/10-90-Report-on-Health-Research-2000
28. Isaakidis P, Swingler GH, Pienaar E, Volmink J, Ioannidis JP. Relation between burden of disease and randomised evidence in sub-Saharan Africa: survey of research. BMJ 2002, 324(7339):702. 10.1136/bmj.324.7339.702, 99053, 11909786.
29. Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA 2004, 291(21):2616-22. 10.1001/jama.291.21.2616, 15173153.
30. European Commission White Paper. Together for Health: A Strategic Approach for the EU 2008-2013 (COM(2007) 630 final) 2007, Brussels: European Commission, (accessed January 14, 2010), European Commission., http://ec.europa.eu/health/ph_overview/Documents/strategy_wp_en.pdf
31. European Medicines Agency The European Medicines Agency Road Map to 2015: The Agency's Contribution to Science, Medicines, Health. Draft for Public Consultation 2010, London: European Medicines Agency, (accessed April 02, 2010), European Medicines Agency., http://www.ema.europa.eu/pdfs/general/direct/directory/29989509en.pdf